NASDAQ: RLMDRelmada Therapeutics Inc Stock
$4.68+0.12 (+2.63%)
Updated Apr 17, 2024
RLMD Price
$4.68
Fair Value Price
$0.14
Market Cap
$141.22M
52 Week Low
$2.36
52 Week High
$7.22
P/E
-1.43x
P/B
1.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$98.79M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$52M
Beta
0.84
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
RLMD Overview
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RLMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RLMD ($4.68) is overvalued by 3,342.8% relative to our estimate of its Fair Value price of $0.14 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RLMD ($4.68) is not significantly undervalued (3,342.8%) relative to our estimate of its Fair Value price of $0.14 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RLMD due diligence checks available for Premium users.
Be the first to know about important RLMD news, forecast changes, insider trades & much more!
RLMD News
Valuation
RLMD fair value
Fair Value of RLMD stock based on Discounted Cash Flow (DCF)
Price
$4.68
Fair Value
$0.14
Overvalued by
3,342.80%
RLMD ($4.68) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RLMD ($4.68) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RLMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RLMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.43x
Industry
15.83x
Market
41.64x
RLMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.65x
Industry
5.83x
RLMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RLMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$25.2M
Profit Margin
0%
RLMD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$97.6M
Liabilities
$12.2M
Debt to equity
0.14
RLMD's short-term assets ($97.51M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RLMD's short-term assets ($97.51M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RLMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RLMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.2M
Investing
$7.7M
Financing
-$98.5k
RLMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RLMD vs Biotech Stocks
Relmada Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.